ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dapagliflozin

Also written as “Dapagliflozin”, “Dapagliflozin 10 mg” and “Dapagliflozin 10mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, Chronic · Heart Failure · Diabetes Mellitus · Diabetes Mellitus, Type 1, led by 14 companies.

Drug pageDapagliflozin: every studyMany companies study it; this page follows only the 131 they lead. All 485 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 2, 2014131 company-led studies, 13 open or runningNext primary completion: Dec 10, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca10910 open or runningphase 4since Jun 2, 2014Sep 9, 2005Dec 10, 2026phase 2 · NCT07222917
LG Chemits history only60 open or runningphase 3since Feb 2, 2020May 24, 2018none ahead
Boryung Pharmaceuticalits history only32 open or runningphase 1since May 26, 2022May 26, 2022none ahead
Dong-A STits history only20 open or runningphase 3since Apr 20, 2020Dec 5, 2018none ahead
Hansoh Pharmaceutical Groupits history only20 open or runningphase 1since Apr 30, 2021Apr 30, 2021none ahead
autotelicbioits history only10 open or runningphase 1since Apr 20, 2021Apr 20, 2021none ahead
Daewoong Pharmaceuticalits history only10 open or runningphase 3since Nov 12, 2020Nov 12, 2020none ahead
Dexa Medica Groupits history only10 open or runningno phasesince Nov 7, 2023Nov 7, 2023none ahead
dong-wha-pharmaceutical-co-ltdits history only10 open or runningphase 1since May 4, 2022May 4, 2022none ahead
George Clinical Ptyits history only10 open or runningphase 4since Nov 3, 2020Nov 3, 2020none ahead
  • Named in AstraZeneca’s own pipeline as zibotentan/dapagliflozin, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Fortrea, Parexel, Ground Zero Pharmaceuticals, PT Equilab International, Bristol-Myers Squibb, Q2 Solutions, PRA Health Sciences, Covance and Antaros Medical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since May 23, 2012.

  1. Aug 24, 2022Phase 2 study in Liver CirrhosisNCT05516498 · 205 enrolled · United States, Australia, Austria and more
  2. Oct 4, 2023Phase 3 study in Kidney DiseasesNCT06087835 · 1,835 enrolled · United States, Argentina, Australia and more
  3. Feb 2, 2024Phase 2 study in Liver CirrhosisNCT06269484 · 73 enrolled · United States, Australia, Belgium and more
  4. Feb 13, 2024Phase 3 study in Renal Insufficiency, ChronicNCT06268873 · 2,554 enrolled · United States, Argentina, Australia and more
  5. Aug 20, 2024Phase 4 study in Renal Insufficiency, ChronicNCT06610526 · 731 enrolled · China
  6. Nov 5, 2024Phase 3 study in Heart FailureNCT06677060 · 11,300 planned · United States, Argentina, Australia and more
  7. Dec 16, 2024Phase 3 study in Renal Insufficiency, ChronicNCT06742723 · 5,000 planned · United States, Argentina, Australia and more
  8. Apr 17, 2025Phase 2 study in Kidney DiseasesNCT06942910 · 224 enrolled · Russia
  9. May 5, 2025Phase 1 study in Lecithin Cholesterol Acyltransferase DeficiencyNCT06979388 · 14 enrolled · United Kingdom
  10. Oct 17, 2025Phase 2 study in Renal Insufficiency, ChronicNCT07222917 · 222 enrolled · United States, Argentina, Bulgaria and more
  11. Feb 5, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07404137 · 26 enrolled · United States
  12. May 29, 2026Phase 3 study in Renal Insufficiency, ChronicNCT07624305 · 2,800 planned · United States, Argentina, Austria and more
  13. Jun 18, 20262 phase 3 studies in Diabetes Mellitus, Type 2NCT07662109, NCT07662044
  14. Jul 13, 2026Phase 1 study in Renal InsufficiencyNCT07754331 · 10 enrolled · United States

Ahead

  1. Dec 10, 2026Primary completion: phase 2 study in Renal Insufficiency, ChronicNCT07222917
  2. Feb 18, 2027Primary completion: phase 3 study in Kidney DiseasesNCT06087835
  3. May 31, 2027Primary completion: phase 4 study in Renal Insufficiency, ChronicNCT06610526
  4. Feb 24, 2028Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT06268873

TargetBeta

“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Upon administration, dapagliflozin selectively targets and inhibits SGLT2, thereby preventing the reabsorption of glucose by the kidneys.”NCIt, read by Claude
“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC5A2

ProgramCompanyFurthest phaseStudies
empagliflozinruleBoehringer Ingelheimphase 4142
ertugliflozinruleMerckphase 422
EnavogliflozinruleDaewoong Pharmaceuticalphase 325
vicadrostatBoehringer Ingelheimphase 316
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12

Studies

The newest 60 of 109 AstraZeneca leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07754331Renal Insufficiency · United States1CompletedOct 6, 202610
NCT07662109Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3RecruitingJul 5, 20282,000
NCT07662044Diabetes Mellitus, Type 2 · United States, Argentina, China and more3RecruitingJul 14, 2028800
NCT07624305Renal Insufficiency, Chronic · United States, Argentina, Austria and more3RecruitingJul 1, 20302,800
NCT07404137Renal Insufficiency, Chronic · United States1CompletedApr 2, 202626
NCT07222917Renal Insufficiency, Chronic · United States, Argentina, Bulgaria and more2Active, not recruitingDec 10, 2026222
NCT06979388Lecithin Cholesterol Acyltransferase Deficiency · United Kingdom1CompletedJul 12, 202514
NCT06942910Kidney Diseases · Russia2Active, not recruitingSep 26, 2026224
NCT06742723Renal Insufficiency, Chronic · United States, Argentina, Australia and more3RecruitingDec 18, 20295,000
NCT06677060Heart Failure · United States, Argentina, Australia and more3RecruitingDec 17, 202911,300
NCT06610526Renal Insufficiency, Chronic · China4Active, not recruitingMay 31, 2027731
NCT06268873Renal Insufficiency, Chronic · United States, Argentina, Australia and more3Active, not recruitingFeb 24, 20282,554
NCT06269484Liver Cirrhosis · United States, Australia, Belgium and more2CompletedDec 11, 202473
NCT06087835Kidney Diseases · United States, Argentina, Australia and more3Active, not recruitingFeb 18, 20271,835
NCT05516498Liver Cirrhosis · United States, Australia, Austria and more2TerminatedMay 22, 2025205
NCT05266404Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus) · Germany1CompletedMay 31, 202246
NCT04991571Renal Insufficiency, Chronic · United States1CompletedOct 22, 202127
NCT04856007Healthy Volunteer · China1CompletedJun 14, 202180
NCT04595370Heart Failure · United States, Belgium, Bulgaria and more2CompletedSep 22, 2023153
NCT04564742Heart Failure · Sweden, United Kingdom3CompletedJul 5, 20234,017
NCT04445714Diabetes Mellitus, Type 2 · India4CompletedMar 14, 2023196
NCT03877237Heart Failure With Reduced Ejection Fraction (HFrEF) · United States, Brazil, Canada and more3CompletedMar 7, 2020313
NCT03877224Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Argentina, Brazil and more3CompletedJul 9, 2020504
NCT03619213Heart Failure With Preserved Ejection Fraction · United States, Argentina, Belgium and more3CompletedMar 27, 20226,263
NCT03608358Diabetes Mellitus, Type 2 · Thailand, Vietnam3TerminatedAug 4, 202041
NCT03387683Diabetes Mellitus, Type 2 · Finland, Sweden4CompletedMar 19, 201953
NCT03344341Diabetes Mellitus, Type 2 · China4TerminatedMay 24, 2019304
NCT03338855Diabetes Mellitus, Type 2 · Netherlands4CompletedNov 4, 201926
NCT03199053Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedFeb 1, 2023256
NCT03169959Diabetes Mellitus, Type 2 · United States1CompletedAug 3, 201785
NCT03138356Diabetes Mellitus, Type 2 · United Kingdom1CompletedNov 28, 2017126
NCT03152084Diabetes Mellitus, Type 2 · Netherlands, Sweden4TerminatedMar 20, 202024
NCT03216278Lecithin Cholesterol Acyltransferase Deficiency · Brazil1CompletedMay 22, 2018284
NCT03036150Renal Insufficiency, Chronic · United States, Argentina, Brazil and more3CompletedJun 12, 20204,304
NCT03036124Heart Failure · United States, Argentina, Brazil and more3CompletedJul 17, 20194,744
NCT02725593Diabetes Mellitus, Type 2 · United States, Hungary, Israel and more3CompletedApr 6, 202072
NCT02719132Diabetes Mellitus, Type 24WithdrawnNov 20170
NCT02722239Diabetes Mellitus, Type 2 · Russian Federation1CompletedMay 5, 201640
NCT02681094Diabetes Mellitus, Type 2 · United States, Canada, Czechia and more3CompletedJul 15, 2017905
NCT02637037Diabetes Mellitus, Type 2 · United States1CompletedApr 7, 201680
NCT02582840Diabetes Mellitus, Type 1 · Japan1CompletedJun 201642
NCT02582814Diabetes Mellitus, Type 1 · Japan3CompletedJun 15, 2017151
NCT02564926Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedJan 15, 2018125
NCT02547935Diabetes Mellitus, Type 2 · United States, Australia, Canada and more3CompletedMay 18, 2018459
NCT02471404Diabetes Mellitus, Type 2 · Czechia, Germany, Hungary and more4CompletedMar 13, 2017939
NCT02460978Diabetes Mellitus, Type 1 · United States, Argentina, Belgium and more3CompletedSep 2, 2017815
NCT02426541Diabetes Mellitus, Type 2 · Finland4CompletedApr 28, 201655
NCT02419612Diabetes Mellitus · United States, Czechia, Germany and more3CompletedAug 29, 2017444
NCT02413398Diabetes Mellitus, Type 2 · United States, Bulgaria, Canada and more3CompletedNov 7, 2017321
NCT02284893Diabetes Mellitus, Type 2 · United States, Hungary, Mexico and more3CompletedSep 20, 2016461
NCT02279407Non-alcoholic Fatty Liver Disease · Sweden2CompletedDec 2015223
NCT02268214Diabetes Mellitus, Type 1 · United States, Australia, Austria and more3CompletedJan 4, 2017833
NCT02223065Diabetes Mellitus, Type 21CompletedDec 201436
NCT02157298Diabetes Mellitus, Type 2 · Japan4CompletedFeb 2015266
NCT02096705Diabetes Mellitus · China, Korea, Republic of, Singapore3CompletedJan 28, 2016477
NCT02060201Diabetes Mellitus, Type 21CompletedMay 201472
NCT01730534Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedSep 11, 201817,190
NCT01662999Diabetes Mellitus, Type 2 · United States1CompletedNov 201242
NCT01646320Diabetes Mellitus, Type 2 · United States, Czech Republic, Mexico and more3CompletedAug 2014320
NCT01606007Diabetes Mellitus, Type 2 · United States, Canada, Korea, Republic of and more3CompletedJan 20141,282

How it is read

Names in the registry

  • “Dapagliflozin”, 90 entries
  • “dapagliflozin”, 18 entries
  • “Dapagliflozin 10 mg”, 6 entries
  • “Dapagliflozin 10mg”, 5 entries
  • “Dapagliflozin/metformin XR 10/1000mg”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.